Welcome to our dedicated page for Taysha Gene Therapies news (Ticker: TSHA), a resource for investors and traders seeking the latest updates and insights on Taysha Gene Therapies stock.
Taysha Gene Therapies, Inc. reports company developments as a clinical-stage biotechnology company advancing adeno-associated virus, or AAV, gene therapies for severe monogenic diseases of the central nervous system. Its lead program, TSHA-102, is an intrathecally delivered, self-complementary AAV9 investigational gene transfer therapy in clinical evaluation for Rett syndrome.
Recurring updates cover TSHA-102 clinical and preclinical data, FDA regulatory interactions and designations, manufacturing and comparability topics, financial results, corporate updates, and employee inducement equity grants under Nasdaq listing rules. Company communications also describe the program’s MECP2 construct design, miRARE technology, and clinical trial activity in Rett syndrome.
Taysha Gene Therapies (Nasdaq: TSHA) will participate in the Guggenheim Genomic Medicines and Rare Disease Day Conference on April 1, 2022, at 4:00 PM ET, and the 21st Annual Needham Virtual Healthcare Conference on April 11, 2022, at 11:45 AM ET. The events will feature discussions led by key executives including RA Session II, Suyash Prasad, and Kamran Alam. Taysha focuses on developing AAV-based gene therapies aimed at curing monogenic diseases of the CNS.
Taysha Gene Therapies (Nasdaq: TSHA) announced participation in two fireside chats at the Oppenheimer 32nd Annual Virtual Healthcare Conference. The first chat, focusing on AAV-based Gene Therapy, will take place on March 14, 2022 at 11:00 am ET. The second chat is scheduled for March 15, 2022 at 1:20 pm ET. The events will feature the company's leadership, including the President, Founder, and CEO, and will be accessible via webcast on the Taysha corporate website.
Taysha Gene Therapies (TSHA) announced promising clinical safety data for its gene therapy targeted at CLN7 Batten disease, presented at the 18th Annual WORLD Symposium. The trial achieved the highest intrathecal dose ever delivered in humans, demonstrating a favorable safety profile with no adverse immune responses or dorsal root ganglia inflammation. The trial, ongoing at UT Southwestern, aims to establish safety and tolerability, with potential implications for a serious, currently untreated disease affecting approximately 4,000 patients globally.
Taysha Gene Therapies, Inc. (Nasdaq: TSHA) has reported promising clinical findings for its gene therapy TSHA-120, aimed at treating giant axonal neuropathy (GAN). The data revealed a clinically significant improvement in MFM32 scores across all therapeutic cohorts after one and three years. Specifically, the high dose cohort showed a 5-point improvement compared to an 8-point decline in natural history by Year 1. Additionally, nerve regeneration was confirmed in biopsies. TSHA-120 demonstrated a favorable safety profile over 53 patient-years.
Taysha Gene Therapies (TSHA) reported positive initial data for TSHA-101, a gene therapy for GM2 gangliosidosis. Patient 1 with Sandhoff disease achieved Hex A enzyme activity at 190% of normal by Month 1 and 288% by Month 3, translating to 58-fold above the asymptomatic level. Patient 2 with Tay-Sachs saw a 5-fold increase at Month 1. This is the first support for a bicistronic vector in humans, aiming to normalize enzyme activity. The therapy was well-tolerated, with further clinical updates expected by year-end.
Taysha Gene Therapies (Nasdaq: TSHA) has announced that RA Session II, its President and CEO, will present a corporate overview at the 40th Annual J.P. Morgan Healthcare Conference on January 13, 2022, at 9:00 AM ET. The presentation will focus on Taysha's mission to develop AAV-based gene therapies aimed at treating monogenic diseases of the central nervous system. A webcast of the presentation will be accessible in the 'Events & Media' section of Taysha's website, with archived access available for 60 days.
Taysha Gene Therapies, Inc. (Nasdaq: TSHA) announces participation of RA Session II, President and CEO, in two panels at the LifeSci Partners 11th Annual Corporate Access Event on January 6, 2022. The first panel, titled Gene Therapy: Reaching its Full Potential, occurs at 11:00 AM ET, while the second, Patient Advocacy: Honing the Skill for Crossover Communications, takes place at 2:00 PM ET. Viewers can access the webcasts through the company's website, which also offers archived versions for 60 days.
Taysha Gene Therapies (NASDAQ: TSHA) announced plans for clinical data updates in January 2022, focusing on TSHA-101 for GM2 gangliosidosis and TSHA-120 for giant axonal neuropathy (GAN). The virtual investor calls will cover preliminary clinical safety data and enzyme activity for TSHA-101, as well as safety and efficacy results for the highest dose of TSHA-120. Taysha aims to discuss the program's status, potential regulatory strategies, and commercialization efforts to improve the lives of patients with monogenic CNS diseases.
Taysha Gene Therapies (NASDAQ: TSHA) has been added to the ICE Biotechnology Index (NYSE: ICEBIO), effective December 20, 2021. This inclusion recognizes its value and platform in the biotechnology sector, focusing on gene therapies for central nervous system disorders. CEO RA Session II emphasized the importance of this validation as the company works towards clinical and regulatory milestones to enhance visibility within the investment community. The ICE Biotechnology Index tracks U.S.-listed biotech companies engaged in therapeutic research and development.
Taysha Gene Therapies (TSHA) reported preliminary clinical safety data for its first-generation CLN7 construct, demonstrating a favorable safety profile with no major adverse events observed. The Data Safety Monitoring Board supported dose escalation to the highest dose of 1.0x1015 viral genomes in humans. Upcoming results will be presented at the 18th Annual WORLDSymposium in February 2022. Additionally, Taysha has designed a next-generation construct aimed at enhancing potency and manufacturability while reducing immunogenicity risks.